<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185458</url>
  </required_header>
  <id_info>
    <org_study_id>90660</org_study_id>
    <secondary_id>300400</secondary_id>
    <nct_id>NCT00185458</nct_id>
  </id_info>
  <brief_title>Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).</brief_title>
  <official_title>A 60-month Non-comparative Study on Bleeding Profiles With Levonorgestrel Intrauterine System in Transition From Reproductive Age Contraception to Menopause Age Endometrial Protection During Estrogen Replacement Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has been designed to look at the transfer from using LNG IUS for contraception
      only, in reproductive age to using it for endometrial protection in menopausal age. The main
      area of interest in the study is the pattern of any vaginal bleeding that occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Bleeding Days</measure>
    <time_frame>Last 90 days in Contraception Phase and first 360 days in Hormone-Replacement Therapy (HRT) Phase</time_frame>
    <description>Measured by using Subject Diaries (Subject Reported Data)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Spotting Days</measure>
    <time_frame>Last 90 days in Contraception Phase and first 360 days in HRT Phase</time_frame>
    <description>Measured by using Subject Diaries (Subject Reported Data)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Successful Treatment</measure>
    <time_frame>Last 90 days in Contraception Phase and first 360 days in HRT Phase</time_frame>
    <description>Definition of successful treatment:
Completion of HRT phase, and
Both, the number of bleeding days and the number of spotting days during HRT was equal to or less than during contraceptive phase, and
The number of bleeding days and the number of spotting days could be calculated for at least 3 out of the first 4 reference periods in HRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of QOL as Measured by Women's Health Questionnaire</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Women's Health Questionnaire (Total Score). For the Total score, the minimum is 36 and maximum is 144. A higher score means the distress and dysfunction are less pronounced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation Rates</measure>
    <time_frame>At entry, at 2 years, at 4 years</time_frame>
    <description>Percentage of subjects continuing in the study at the given time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS))</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 4: Nausea (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 5: Edema (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 1: Hot Flushes (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 4: Sleep Problems (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 5: Irritability (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Climacteric Symptom 6: Breast Tension (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 7: Hair Loss (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS)</measure>
    <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
    <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Menopause</condition>
  <arm_group>
    <arm_group_label>LNG IUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG IUS</intervention_name>
    <description>LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
    <arm_group_label>LNG IUS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with intact uterus, regular menstrual cycles and no previous or current
             climacteric symptoms.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Previous pelvic infections.

          -  Abnormal bleeding.

          -  Abnormal uterine cavity.

          -  Uterine polyps.

          -  Genital cancer.

          -  Liver diseases.

          -  Alcoholism or drug abuse.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>46 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>HUY</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaandam</city>
        <zip>1502 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB23 2TN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Depypere HT, Hillard T, Erkkola R, Lukkari-Lax E, Kunz M, Rautiainen P, Schram JH. A 60-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause. Eur J Obstet Gynecol Reprod Biol. 2010 Dec;153(2):176-80. doi: 10.1016/j.ejogrb.2010.08.017.</citation>
    <PMID>20888118</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>July 23, 2009</results_first_submitted>
  <results_first_submitted_qc>October 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2009</results_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Only the subjects who reached menopause within max. of 4 years of the contraception phase were eligible for the Hormone-Replacement Therapy (HRT) phase. 58 subjects discontinued the study during the contraception phase before starting the HRT, and 168 subjects who started treatment did not reach menopause.</recruitment_details>
      <pre_assignment_details>489 subjects were screened: 394 subjects started treatment and 95 subjects failed screening. Intent-to-treat (ITT) population included all subjects (N=394) who had the LNG IUS inserted, or for whom the insertion was attempted. 322 subjects without major protocol deviations were included in the Per protocol set (PPS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LNG IUS</title>
          <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Contraception Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>HRT Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168">168 subjects were eligible for the HRT phase out 336 who completed contraception phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LNG IUS</title>
          <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="394"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding Days</title>
        <description>Measured by using Subject Diaries (Subject Reported Data)</description>
        <time_frame>Last 90 days in Contraception Phase and first 360 days in Hormone-Replacement Therapy (HRT) Phase</time_frame>
        <population>Intention to treat population (ITT); all subjects with adequate bleeding diary data. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Period -1 (Contraception Phase)</title>
            <description>Patient assessment within the last 90-days before starting the HRT</description>
          </group>
          <group group_id="O2">
            <title>Reference Period 1 (HRT Phase)</title>
            <description>Patient assessment within the first 90-days of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>Reference Period 2 (HRT Phase)</title>
            <description>Patient assessment within day 91 to 180 of the HRT phase</description>
          </group>
          <group group_id="O4">
            <title>Reference Period 3 (HRT Phase)</title>
            <description>Patient assessment within day 181 to 270 of the HRT phase</description>
          </group>
          <group group_id="O5">
            <title>Reference Period 4 (HRT Phase)</title>
            <description>Patient assessment within day 271 to 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding Days</title>
          <description>Measured by using Subject Diaries (Subject Reported Data)</description>
          <population>Intention to treat population (ITT); all subjects with adequate bleeding diary data. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>Bleeding days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time effect tested with Friedman's two-way analysis of variance (ANOVA). The null-hypothesis is that the means are equal at the reference period tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.128</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Spotting Days</title>
        <description>Measured by using Subject Diaries (Subject Reported Data)</description>
        <time_frame>Last 90 days in Contraception Phase and first 360 days in HRT Phase</time_frame>
        <population>ITT; all subjects with adequate bleeding diary data. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Reference Period -1 (Contraception Phase)</title>
            <description>Patient assessment within the last 90-days before starting the HRT</description>
          </group>
          <group group_id="O2">
            <title>Reference Period 1 (HRT Phase)</title>
            <description>Patient assessment within the first 90-days of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>Reference Period 2 (HRT Phase)</title>
            <description>Patient assessment within day 91 to 180 of the HRT phase</description>
          </group>
          <group group_id="O4">
            <title>Reference Period 3 (HRT Phase)</title>
            <description>Patient assessment within day 181 to 270 of the HRT phase</description>
          </group>
          <group group_id="O5">
            <title>Reference Period 4 (HRT Phase)</title>
            <description>Patient assessment within day 271 to 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Spotting Days</title>
          <description>Measured by using Subject Diaries (Subject Reported Data)</description>
          <population>ITT; all subjects with adequate bleeding diary data. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>Spotting days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
                <count group_id="O4" value="141"/>
                <count group_id="O5" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time effect tested with Friedman's two-way analysis of variance (ANOVA). The null-hypothesis is that the means are equal at the reference period tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.296</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Successful Treatment</title>
        <description>Definition of successful treatment:
Completion of HRT phase, and
Both, the number of bleeding days and the number of spotting days during HRT was equal to or less than during contraceptive phase, and
The number of bleeding days and the number of spotting days could be calculated for at least 3 out of the first 4 reference periods in HRT</description>
        <time_frame>Last 90 days in Contraception Phase and first 360 days in HRT Phase</time_frame>
        <population>ITT; all subjects eligible for the HRT</population>
        <group_list>
          <group group_id="O1">
            <title>LNG IUS</title>
            <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Successful Treatment</title>
          <description>Definition of successful treatment:
Completion of HRT phase, and
Both, the number of bleeding days and the number of spotting days during HRT was equal to or less than during contraceptive phase, and
The number of bleeding days and the number of spotting days could be calculated for at least 3 out of the first 4 reference periods in HRT</description>
          <population>ITT; all subjects eligible for the HRT</population>
          <units>Percentage of participants with success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of QOL as Measured by Women's Health Questionnaire</title>
        <description>Women's Health Questionnaire (Total Score). For the Total score, the minimum is 36 and maximum is 144. A higher score means the distress and dysfunction are less pronounced.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of QOL as Measured by Women's Health Questionnaire</title>
          <description>Women's Health Questionnaire (Total Score). For the Total score, the minimum is 36 and maximum is 144. A higher score means the distress and dysfunction are less pronounced.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="17.75"/>
                    <measurement group_id="O2" value="114.4" spread="16.64"/>
                    <measurement group_id="O3" value="112.9" spread="16.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuation Rates</title>
        <description>Percentage of subjects continuing in the study at the given time points.</description>
        <time_frame>At entry, at 2 years, at 4 years</time_frame>
        <population>ITT. Kaplan-Meier estimator given.</population>
        <group_list>
          <group group_id="O1">
            <title>LNG IUS</title>
            <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation Rates</title>
          <description>Percentage of subjects continuing in the study at the given time points.</description>
          <population>ITT. Kaplan-Meier estimator given.</population>
          <units>Percentage of participants continuing</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Entry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS))</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 1: Headache (as Measured by a Visual Analogue Scale (VAS))</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="23.98"/>
                    <measurement group_id="O2" value="19.1" spread="22.57"/>
                    <measurement group_id="O3" value="18.2" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 2: Depressive Mood (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="25.69"/>
                    <measurement group_id="O2" value="11.8" spread="17.31"/>
                    <measurement group_id="O3" value="14.6" spread="22.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 3: Acne or Greasy Skin (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="14.02"/>
                    <measurement group_id="O2" value="7.3" spread="15.38"/>
                    <measurement group_id="O3" value="7.6" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 4: Nausea (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 4: Nausea (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="13.57"/>
                    <measurement group_id="O2" value="5.3" spread="11.96"/>
                    <measurement group_id="O3" value="6.7" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 5: Edema (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 5: Edema (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="20.30"/>
                    <measurement group_id="O2" value="12.3" spread="18.93"/>
                    <measurement group_id="O3" value="11.7" spread="17.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 6: Decreased Libido (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.9" spread="26.29"/>
                    <measurement group_id="O2" value="15.6" spread="22.06"/>
                    <measurement group_id="O3" value="17.5" spread="21.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 1: Hot Flushes (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 1: Hot Flushes (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="30.21"/>
                    <measurement group_id="O2" value="9.4" spread="14.88"/>
                    <measurement group_id="O3" value="11.3" spread="18.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 2: Sweating Episodes (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" spread="29.40"/>
                    <measurement group_id="O2" value="14.0" spread="19.95"/>
                    <measurement group_id="O3" value="17.0" spread="21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 3: Vaginal Dryness (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="27.96"/>
                    <measurement group_id="O2" value="13.1" spread="20.93"/>
                    <measurement group_id="O3" value="16.7" spread="23.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 4: Sleep Problems (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 4: Sleep Problems (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="29.71"/>
                    <measurement group_id="O2" value="17.1" spread="21.34"/>
                    <measurement group_id="O3" value="19.9" spread="23.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 5: Irritability (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 5: Irritability (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="27.40"/>
                    <measurement group_id="O2" value="17.2" spread="19.47"/>
                    <measurement group_id="O3" value="19.4" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Climacteric Symptom 6: Breast Tension (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Climacteric Symptom 6: Breast Tension (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="22.16"/>
                    <measurement group_id="O2" value="13.5" spread="20.39"/>
                    <measurement group_id="O3" value="13.0" spread="19.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 7: Hair Loss (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 7: Hair Loss (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="15.14"/>
                    <measurement group_id="O2" value="9.3" spread="16.69"/>
                    <measurement group_id="O3" value="9.0" spread="13.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS)</title>
        <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
        <time_frame>Last measurement before start of HRT phase, 6 months after start of HRT phase, 12 month after start of HRT phase</time_frame>
        <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Last Measurement Before Start of HRT Phase</title>
            <description>Patient assessment at the end of contraception phase</description>
          </group>
          <group group_id="O2">
            <title>6 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 180 of the HRT phase</description>
          </group>
          <group group_id="O3">
            <title>12 Months After Start of HRT Phase</title>
            <description>Patient assessment about day 360 of the HRT phase</description>
          </group>
        </group_list>
        <measure>
          <title>Progestogenic Symptom 8: Greasy Hair (as Measured by a VAS)</title>
          <description>Higher value means the symptom is more pronounced. Minimum is 0, maximum is 100.</description>
          <population>ITT. Only the subjects that were eligible for the HRT are included. Due to dropouts and missing data the number of subjects do not necessarily sum up to 168, the number of subjects of the ITT, who qualified for the HRT phase.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="20.60"/>
                    <measurement group_id="O2" value="11.5" spread="18.85"/>
                    <measurement group_id="O3" value="11.1" spread="18.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a Friedman's two-way analysis of variance (ANOVA) to test the time effect within the treatment group. The null-hypothesis is that the means are equal at the time points tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Friedman's two-way ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The data covers the entire treatment period (contraception phase + HRT phase).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LNG IUS</title>
          <description>Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Jejunectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Splenectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="357" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear cervix normal</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Genital haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigators agree to allow the sponsor to review any manuscripts and to negotiate the times and forums of their publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

